Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual. Familial hypercholesterolemia (FH) is the inheritable form of hypercholesterolemia and is characterized by elevated levels of total cholesterol and LDL cholesterol. Heterozygous familial hypercholesterolemia (HeFH) is the condition inherited because of the presence of one abnormal copy of the LDLR gene. Homozygous familial hypercholesterolemia (HoFH) is characterized by the presence of abnormal copies of both the LDLR alleles.

 PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

Drug profiles

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Clinical application

Treatment guidelines

Key buying criteria

PART 05: Hypercholesterolemia: An overview

History of hypercholesterolemia

Hypercholesterolemia management market dynamics

Hypercholesterolemia prescription landscape

Management of hypercholesterolemia

Epidemiology

Unmet medical needs and role of PCSK9 and CETP

inhibitors

PART 06: Pipeline portfolio

Information on pipeline candidates

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Segmentation by type of disease

FH

Non-FH

PART 09: Market segmentation by MOA

HMG-CoA reductase inhibitors

Fibric acid derivatives

Nicotinic acid

Bile acid sequestrants

Other

PART 10: Market segmentation by drug class

Statins

Non-statins

PART 11: Geographical segmentation

Global hypercholesterolemia drugs market by

geographical segmentation 2015-2020

Hypercholesterolemia drugs market in Americas

Hypercholesterolemia drugs market in EMEA

Hypercholesterolemia drugs market in APAC

PART 12: Market drivers

Increasing risk of CVDs

Rising prevalence of chronic diseases

Promising pipeline of drugs

Change in ATP guidelines for management of

hypercholesterolemia

Growing older population

PART 13: Impact of drivers

PART 14: Market challenges

Loss of patent exclusivity of branded therapies

Drawbacks associated with current therapies

High cost of therapy

Stringent regulatory guidelines

Lack of proper diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends

Expected entry of cost-effective OTC versions

Increasing use of statins

Increased use of combination therapies

Consideration of lifestyle management in ATP

guidelines

PART 17: Vendor landscape

Competitive scenario 69

Market share analysis 2015 71

PART 18: Key vendor analysis 73

AbbVie 73

Aegerion Pharmaceuticals 76

AstraZeneca 78

Merck 81

Pfizer 84

Sanofi 88

Other prominent vendors 90

PART 19: Appendix 95

List of abbreviations 95

PART 20: Explore Technavio 96